[go: up one dir, main page]

JPH09500087A - カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法 - Google Patents

カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法

Info

Publication number
JPH09500087A
JPH09500087A JP6502621A JP50262194A JPH09500087A JP H09500087 A JPH09500087 A JP H09500087A JP 6502621 A JP6502621 A JP 6502621A JP 50262194 A JP50262194 A JP 50262194A JP H09500087 A JPH09500087 A JP H09500087A
Authority
JP
Japan
Prior art keywords
leu
group
mammal
alkyl
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6502621A
Other languages
English (en)
Japanese (ja)
Inventor
エベレス，デイビッド，ディー．，ジュニア
リンチ，ゲリー
シー． パワーズ，ジャームズ
ティー． バータス，レイモンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgia Tech Research Corp
Original Assignee
Georgia Tech Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia Tech Research Corp filed Critical Georgia Tech Research Corp
Publication of JPH09500087A publication Critical patent/JPH09500087A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP6502621A 1992-06-24 1993-06-24 カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法 Pending JPH09500087A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US90380092A 1992-06-24 1992-06-24
US3499693A 1993-03-16 1993-03-16
US7260993A 1993-06-01 1993-06-01
US08/072,609 1993-06-01
US07/903,800 1993-06-01
US08/034,996 1993-06-01
PCT/US1993/006143 WO1994000095A2 (fr) 1992-06-24 1993-06-24 Emploi d'inhibiteurs de calpaine dans l'inhibition et le traitement d'etats medicaux associes a une activite de calpaine accrue

Publications (1)

Publication Number Publication Date
JPH09500087A true JPH09500087A (ja) 1997-01-07

Family

ID=27364781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6502621A Pending JPH09500087A (ja) 1992-06-24 1993-06-24 カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法

Country Status (5)

Country Link
EP (1) EP0650368A1 (fr)
JP (1) JPH09500087A (fr)
AU (1) AU4544993A (fr)
CA (1) CA2138124A1 (fr)
WO (1) WO1994000095A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538212A (ja) * 2005-03-21 2008-10-16 アプレラ コーポレイション システインプロテアーゼ阻害剤としてのアルファケトアミド化合物
JP2016210716A (ja) * 2015-05-07 2016-12-15 国立大学法人山口大学 ＳＰＣ／Ｆｙｎ／Ｒｈｏキナーゼシグナル伝達経路の阻害剤
JP2021535093A (ja) * 2018-08-13 2021-12-16 ウェスタン ユニバーシティ オブ ヘルス サイエンシズ 緑内障の治療のためのカルパイン−２選択的阻害剤化合物

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541290A (en) * 1993-06-24 1996-07-30 Harbeson; Scott L. Optically pure calpain inhibitor compounds
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
WO1996016079A2 (fr) * 1994-11-24 1996-05-30 Takeda Chemical Industries, Ltd Derives d'alpha-cetoamide utilises comme inhibiteurs de cathepsine l
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5827877A (en) 1995-09-14 1998-10-27 Cephalon, Inc. Ketomethylene group-containing cysteine and serine protease inhibitors
US5723580A (en) * 1995-09-14 1998-03-03 Cephalon, Inc. Ketomethylene group-containing aldehyde cysteine and serine protease inhibitors
SK56798A3 (en) 1995-10-30 1998-12-02 Smithkline Beecham Corp Protease inhibitors, pharmaceutical composition containing them and their use
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
DE69637307T2 (de) * 1995-11-28 2008-02-28 Cephalon, Inc. Aus d-aminosäuren abgeleitete cystein-und serinproteasehemmer
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
DE19642591A1 (de) * 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
US6303579B1 (en) 1996-10-31 2001-10-16 Alcon Laboratories, Inc. Use of calpain inhibitors to treat ocular neural pathology
DE19650975A1 (de) 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
US6103720A (en) * 1996-12-11 2000-08-15 Basf Aktiengesellschaft Ketobenzamides as calpain inhibitors
JP2002161051A (ja) * 1996-12-24 2002-06-04 Fujisawa Pharmaceut Co Ltd 脳虚血性疾患等の治療剤
DE19818614A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Amide, deren Herstellung und Anwendung
ID26403A (id) 1998-04-20 2000-12-21 Basf Ag Amida baru yang tersubstitusi, pembuatan dan penggunaannya
EP1082308B1 (fr) 1998-04-20 2009-04-01 Abbott GmbH & Co. KG Amides substitues par voie heterocyclique et utilises comme inhibiteurs de calpaine
DE19817459A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
US6841537B1 (en) 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
US6841538B1 (en) * 1998-04-22 2005-01-11 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and radio therapy
AU762986B2 (en) * 1998-04-22 2003-07-10 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and conventional drugs
IL139357A0 (en) 1998-05-25 2001-11-25 Basf Ag New heterocyclically substituted amides, their production and their use
DE19847422C1 (de) * 1998-10-14 2000-01-13 Forschungszentrum Juelich Gmbh Chinese-Hamster-Ovary-Zellen zur Produktion von Proteinen
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
JP2003513971A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
WO2001034600A1 (fr) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Inhibiteurs de protease
CN1416346A (zh) 2000-03-21 2003-05-07 史密丝克莱恩比彻姆公司 蛋白酶抑制剂
MXPA03000626A (es) 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
MY143322A (en) 2000-07-21 2011-04-15 Schering Corp Peptides as ns3-serine protease inhibitors of hepatitis c virus
GB0106051D0 (en) * 2001-03-12 2001-05-02 Isis Innovation Diagnostic screens for alzheimer's disease
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US6610874B2 (en) 2001-09-28 2003-08-26 Pcbu Services, Inc. Processes and compositions for the production of chiral amino-nitriles
WO2003062192A1 (fr) 2002-01-17 2003-07-31 Smithkline Beecham Corporation Derives de cetoamides a substitution cycloalkyle, utiles comme inhibiteurs de cathepsine k
EP1692098B1 (fr) * 2003-12-12 2009-10-28 Senju Pharmaceutical Co., Ltd. Derive d'alpha-cetoamide, son procede de production et d'utilisation
GB2467562A (en) * 2009-02-06 2010-08-11 Summit Corp Plc Dual calpain-ROS inhibitors
WO2013067415A1 (fr) * 2011-11-02 2013-05-10 Tufts University Identification et utilisation d'inhibiteurs de protéase pour traiter ou prévenir une drépanocytose
CN102988336A (zh) * 2012-05-17 2013-03-27 中国人民解放军第二军医大学 Tpck用于制备抗晶状体混浊产品的用途
WO2016038040A2 (fr) * 2014-09-08 2016-03-17 Landsteiner Genmed, S.L. Composés dipeptidyl-cétoamide et leur utilisation pour le traitement et/ou la prévention de l'accumulation de graisse
WO2017156071A1 (fr) * 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Composés céto-amides cycliques utilisés en tant que modulateurs de la calpaïne, et leurs procédés de production et d'utilisation
EP3481835A4 (fr) 2016-07-05 2020-02-26 Blade Therapeutics, Inc. Modulateurs de calpain et leurs utilisations thérapeutiques
PE20191153A1 (es) 2016-09-28 2019-09-05 Blade Therapeutics Inc Moduladores de calpainas y usos terapeuticos de los mismos
PE20212111A1 (es) * 2018-03-28 2021-11-04 Blade Therapeutics Inc Moduladores calpaina y usos terapeuticos de los mismos
EP3774785A4 (fr) * 2018-03-28 2021-12-01 Blade Therapeutics, Inc. Méthode de traitement d'un trouble fibrotique
EP4488264A1 (fr) * 2022-03-01 2025-01-08 WestVac Biopharma Co., Ltd. Dérivés de ceto amide et leur utilisation pharmaceutique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US4771123A (en) * 1986-03-11 1988-09-13 Enzyme Systems Products, Inc. Peptide thioneamides as selective substrates for cysteine proteases
NZ223148A (en) * 1987-01-16 1989-10-27 Merrell Dow Pharma Peptide derivatives having peptidase inhibition activity
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
US5189144A (en) * 1989-04-28 1993-02-23 Takara Shuzo Co., Ltd. Human calpastatin-like polypeptide

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538212A (ja) * 2005-03-21 2008-10-16 アプレラ コーポレイション システインプロテアーゼ阻害剤としてのアルファケトアミド化合物
JP2012254985A (ja) * 2005-03-21 2012-12-27 Virobay Inc システインプロテアーゼ阻害剤としてのアルファケトアミド化合物
KR101447897B1 (ko) * 2005-03-21 2014-10-07 비로베이, 인코포레이티드 시스테인 단백질분해효소 억제제로서의 알파 케토아미드화합물
JP2016210716A (ja) * 2015-05-07 2016-12-15 国立大学法人山口大学 ＳＰＣ／Ｆｙｎ／Ｒｈｏキナーゼシグナル伝達経路の阻害剤
JP2021535093A (ja) * 2018-08-13 2021-12-16 ウェスタン ユニバーシティ オブ ヘルス サイエンシズ 緑内障の治療のためのカルパイン−２選択的阻害剤化合物
JP2024150552A (ja) * 2018-08-13 2024-10-23 ウェスタン ユニバーシティ オブ ヘルス サイエンシズ 緑内障の治療のためのカルパイン－２選択的阻害剤化合物

Also Published As

Publication number Publication date
WO1994000095A2 (fr) 1994-01-06
WO1994000095A3 (fr) 1994-03-17
CA2138124A1 (fr) 1994-01-06
AU4544993A (en) 1994-01-24
EP0650368A1 (fr) 1995-05-03

Similar Documents

Publication Publication Date Title
JPH09500087A (ja) カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法
AU667463B2 (en) Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
US5444042A (en) Method of treatment of neurodegeneration with calpain inhibitors
US5610297A (en) Peptides ketoamides
JP4439111B2 (ja) ジペプチドのアポトーシスインヒビターおよびそれらの使用
US5763576A (en) Tetrapeptide α-ketoamides
JP2004531466A (ja) 血管新生を調節するための治療薬およびその使用方法
EP0564561A1 (fr) Cetoamides, cetoacides et cetoesters peptidiques
EP0356223A2 (fr) Inhibiteurs de HIV-protéase utiles pour le traitement du SIDA
JPS63253061A (ja) チオールプロテアーゼ阻害剤としてのアリールオキシおよびアリールアシルオキシメチルケトン
DE10143840A1 (de) Neue Inhibitoren der Dipeptidylpeptidase I
EP0586537A1 (fr) Derives substitues n-carboxyalkylpeptidyle en tant qu'agents antidegeneratifs
US6235929B1 (en) Tripeptide α-ketoamides
JPH08503475A (ja) 抗変性活性剤としてのカルボキシ−ペプチジル誘導体
US5679700A (en) Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
JPH02256657A (ja) Ｎ―置換アミド
US5846755A (en) Method for determining the therapeutic activity of metalloproteinase inhibitor compounds
WO2004005270A1 (fr) Epoxydes d'aza-peptides
KR20000016700A (ko) 뎁시 펩티드 및 이를 유효 성분으로 하는 의약
AU2005214388A1 (en) Propenoyl hydrazides
US6090785A (en) Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents
JP2003502442A (ja) セリンエラスターゼの活性を阻害する方法及び化合物
US6593300B1 (en) (3R)-3-amino-4-carboxybutyraldehyde derivatives inhibiting the release of interleukin-1/beta
JP6326232B2 (ja) 関節症の処置のためのアミノスタチン誘導体
AU2378299A (en) Use of calpain inhibitors in the inhibition and treatment of neurodegeneration